ReviewDrug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy2020
COVID-19 update: The race to therapeutic development.
Review in Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- When stem cells meet COVID-19: recent advances, challenges and future perspectives.Stem cell research & therapy · 2022Pooled it
- Current status of coronavirus disease 2019 vaccine research based on bibliometric analysis.Human vaccines & immunotherapeutics · 2022Trial
- Evaluation of Biologics ACE2/Ang(1-7) Encapsulated in Plant Cells for FDA Approval: Safety and Toxicology Studies.Pharmaceutics · 2024Article
- Bacterial Membrane Vesicles as a Novel Vaccine Platform against SARS-CoV-2.Current microbiology · 2024Review
- Marine-Derived Bioactive Metabolites as a Potential Therapeutic Intervention in Managing Viral Diseases: Insights from the SARS-CoV-2 In Silico and Pre-Clinical Studies.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 helicase inhibitors: a systematic review ofJournal of virus eradication · 2023Review
- Novel Polymyxin-Inspired Peptidomimetics Targeting the SARS-CoV-2 Spike:hACE2 Interface.International journal of molecular sciences · 2023Article
- Molecular recognition of SARS-CoV-2 spike protein with three essential partners: exploring possible immune escape mechanisms of viral mutants.Journal of molecular modeling · 2023Article
- Comparative Assessment of the Binding and Neutralisation Activity of Bispecific Antibodies Against SARS-CoV-2 Variants.Antibody therapeutics · 2023Article
- Preclinical efficacy and safety of novel SNAT against SARS-CoV-2 using a hamster model.Drug delivery and translational research · 2022Article
- Elucidating host cell response pathways and repurposing therapeutics for SARS-CoV-2 and other coronaviruses.Scientific reports · 2022Article
- Biophysical and Biochemical Characterization of the Receptor Binding Domain of SARS-CoV-2 Variants.The protein journal · 2022Article
- SARS-CoV-2 variant trends in Ireland: Wastewater-based epidemiology and clinical surveillance.The Science of the total environment · 2022Article
- Decrease in Angiotensin-Converting Enzyme activity but not concentration in plasma/lungs in COVID-19 patients offers clues for diagnosis/treatment.Molecular therapy. Methods & clinical development · 2022Article
- Normalized COVID-19 prevention and control management.Journal of family medicine and primary care · 2022Article
- Designing and characterization of a SARS-CoV-2 immunogen with receptor binding motif grafted on a protein scaffold: An epitope-focused vaccine approach.International journal of biological macromolecules · 2022Article
- Mitoxantrone modulates a heparan sulfate-spike complex to inhibit SARS-CoV-2 infection.Scientific reports · 2022Article
- Induction of Innate Immune Response by TLR3 Agonist Protects Mice against SARS-CoV-2 Infection.Viruses · 2022Article
- Predicting the aggravation of coronavirus disease-19 pneumonia using chest computed tomography scans.PloS one · 2022Article
- Non-clinical safety assessment and in vivo biodistribution of CoviFab, an RBD-specific F(ab')2 fragment derived from equine polyclonal antibodies.Toxicology and applied pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), represents an unprecedented challenge to global public health. At the time of this review, COVID-19 has been diagnosed in over 40 million cases and associated with 1.1 million deaths worldwide. Current management strategies for COVID-19 are largely supportive, and while there are more than 2000 interventional clinical trials registered with the U.S. National Library of Medicine (clinicaltrials.gov), results that can clarify benefits and risks of candidate therapies are only gradually becoming available. We herein describe recent advances in understanding SARS-CoV-2 pathobiology and potential therapeutic targets that are involved in viral entry into host cells, viral spread in the body, and the subsequent COVID-19 progression. We highlight two major lines of therapeutic strategies for COVID-19 treatment: 1) repurposing the existing drugs for use in COVID-19 patients, such as antiviral medications (e.g., remdesivir) and immunomodulators (e.g., dexamethasone) which were previously approved for other disease conditions, and 2) novel biological products that are designed to target specific molecules that are involved in SARS-CoV-2 viral entry, including neutralizing antibodies against the spike protein of SARS-CoV-2, such as REGN-COV2 (an antibody cocktail), as well as recombinant human soluble ACE2 protein to counteract SARS-CoV-2 binding to the transmembrane ACE2 receptor in target cells. Finally, we discuss potential drug resistance mechanisms and provide thoughts regarding clinical trial design to address the diversity in COVID-19 clinical manifestation. Of note, preventive vaccines, cell and gene therapies are not within the scope of the current review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.